昭栄薬品 raised its consolidated earnings forecast for the fiscal year ending March 2027 and increased its year-end dividend by ¥2 to ¥43. Revenue is expected to reach a record high of ¥30.149 billion, with operating profit at ¥686 million, among other figures.
昭栄薬品 raised its full-year consolidated earnings forecast for the fiscal year ending March 2027. Revenue is expected to increase from ¥27.267 billion to ¥30.149 billion, operating profit from ¥441 million to ¥686 million, ordinary profit from ¥629 million to ¥854 million, and net income attributable to owners of the parent from ¥437 million to ¥588 million. Revenue and each profit item are expected to reach record highs.
During the cumulative second quarter, orders from major domestic customers in the chemicals business increased, and the company passed on higher selling prices against a backdrop of persistently high natural oils prices. Subsidiaries in Shanghai and Thailand also performed well, while the household products and civil engineering and construction materials businesses remained firm. The company made its assessment after comprehensively considering geopolitical risks, raw material prices, exchange-rate trends and other uncertain factors, as well as recent order conditions and earnings progress.
In light of the upside in net income, the company raised its year-end dividend under its progressive dividend policy from ¥41 to ¥43. The payout ratio is expected to be 25.1%.